Literature DB >> 26390970

Prostate cancer: Growth of AS in the USA signals reduction in overtreatment.

Declan G Murphy1, Stacy Loeb2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26390970     DOI： 10.1038/nrurol.2015.236

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.

Authors:  Paul R Womble; James E Montie; Zaojun Ye; Susan M Linsell; Brian R Lane; David C Miller
Journal:  Eur Urol       Date:  2014-08-24       Impact factor: 20.096

Review 2.  The Melbourne Consensus Statement on the early detection of prostate cancer.

Authors:  Declan G Murphy; Thomas Ahlering; William J Catalona; Helen Crowe; Jane Crowe; Noel Clarke; Matthew Cooperberg; David Gillatt; Martin Gleave; Stacy Loeb; Monique Roobol; Oliver Sartor; Tom Pickles; Addie Wootten; Patrick C Walsh; Anthony J Costello
Journal:  BJU Int       Date:  2014-02       Impact factor: 5.588

3.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

4.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

Authors:  Matthew R Cooperberg; Peter R Carroll
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

5.  Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.

Authors:  Daniel A Barocas; Katherine Mallin; Amy J Graves; David F Penson; Bryan Palis; David P Winchester; Sam S Chang
Journal:  J Urol       Date:  2015-06-15       Impact factor: 7.450

6.  The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.

Authors:  Mahesha Weerakoon; Nathan Papa; Nathan Lawrentschuk; Sue Evans; Jeremy Millar; Mark Frydenberg; Damien Bolton; Declan G Murphy
Journal:  BJU Int       Date:  2015-04       Impact factor: 5.588

7.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

8.  Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

Authors:  Bimal Bhindi; Muhammad Mamdani; Girish S Kulkarni; Antonio Finelli; Robert J Hamilton; John Trachtenberg; Alexandre R Zlotta; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Neil E Fleshner
Journal:  J Urol       Date:  2014-12-03       Impact factor: 7.450

9.  Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

Authors:  Stacy Loeb; Anders Berglund; Pär Stattin
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450
  9 in total
  7 in total

1.  Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?

Authors:  Theodorus H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2017-06-13       Impact factor: 14.432

2.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Authors:  Joshua A Roth; Roman Gulati; John L Gore; Matthew R Cooperberg; Ruth Etzioni
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

3.  Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging.

Authors:  Ridwan Alam; H Ballentine Carter; Jonathan I Epstein; Jeffrey J Tosoian
Journal:  Rev Urol       Date:  2017

Review 4.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

5.  Trends in treatments for prostate cancer in the United States, 2010-2015.

Authors:  Jianwei Wang; Harry Hua-Xiang Xia; Yuanyuan Zhang; Lanjing Zhang
Journal:  Am J Cancer Res       Date:  2021-05-20       Impact factor: 6.166

Review 6.  Expanded criteria for active surveillance in prostate cancer: a review of the current data.

Authors:  Cameron Jones; Mina M Fam; Benjamin J Davies
Journal:  Transl Androl Urol       Date:  2018-04

7.  Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners.

Authors:  Penelope Schofield; Karla Gough; Amelia Hyatt; Alan White; Mark Frydenberg; Suzanne Chambers; Louisa G Gordon; Robert Gardiner; Declan G Murphy; Lawrence Cavedon; Natalie Richards; Barbara Murphy; Stephen Quinn; Ilona Juraskova
Journal:  Trials       Date:  2021-01-11       Impact factor: 2.279
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.